A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
第2相
完了
NCT01797523
| 対象疾患 | Endometrial Cancer |
|---|
| 相 | 第2相 |
|---|
| スポンサー | M.D. Anderson Cancer Center |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 62 名 |
|---|
| 介入（薬剤） | Metformin, Letrozole, Everolimus |
|---|
| 開始日 | 2013年10月7日 |
|---|
| 完了日 | 2026年2月4日 |
|---|
| 結果公開日 | 2026年7月30日 |
|---|
概要
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied. Everolimus is designed to block a protein inside cancer cells that is involved in cancer growth. Letrozole is designed to block a protein from making estrogen. This may interfere with the growth of cancer cells. Metformin is commonly used to control blood sugar levels in patients with diabetes. It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells.
Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.
93 months · Participants
| Rad-Let-Met | 27 Participants |
|---|
| Rad-Let-Met | 15 Participants |
|---|
| Rad-Let-Met | 12 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。